Joint-Stock Company "Medsi Group of Companies"
Joint-Stock Company "Medsi Group of Companies"
Moscow, Russia2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 2 | 2026-04-28 | NCT07553988 | |
| A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-04-22 | NCT07543744 |